Navigation Links
TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Date:9/10/2007

LA JOLLA, Calif., Sept. 10 /PRNewswire-FirstCall/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced completion of its third Phase I clinical trial for NGX267, in clinical development for the treatment of cognitive impairment associated with schizophrenia (CIAS). The compound, a functionally selective muscarinic (M1) agonist, was found to be safe and well-tolerated when given orally to healthy male volunteers once-daily for four consecutive days. In two previous Phase I trials, NGX267, administered as single oral doses, was shown to be well-tolerated in healthy young adult males, as well as in healthy elderly males and females.

The purpose of the Phase I trial was to investigate the safety, tolerability and pharmacokinetics of multiple doses of NGX267 and to confirm data from previous studies in which NGX267 demonstrated evidence of muscarinic receptor stimulation as measured by increases in salivary flow. A total of 60 healthy males, between the ages of 18 and 55, were enrolled in the double-blind, placebo-controlled trial conducted at one center in Belgium. In a series of sequential dosing cohorts, subjects received a single oral dose of either 10, 20, 30 or 35 mg of NGX267 once-daily for four consecutive days. NGX267 was well tolerated at doses up to and including 30 mg, a dose range believed to be effective for treating memory and cognitive disturbances. TorreyPines plans to initiate a Phase II dose-ranging trial in CIAS during the first half of 2008.

A secondary objective was to obtain quantitative measures of salivary flow, prior to and at multiple time points post-dosing, as a peripheral biomarker for stimulation of the muscarinic receptor. In the study, increases in peak and total sal
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014   Medical Equipment Solutions, Corp. ... awarded a Department of Defense (US Army) contract valued ... a mobile MRI diagnostic machine and technical support staffing. ... through the Small Business Administration (SBA), Medical Equipment is ... with the latest medical diagnostic equipment. The SBA 8-A ...
(Date:7/30/2014)... , July 30, 2014   Epic Sciences, ... that designs and develops novel diagnostics to personalize ... announced today the completion of a $30 million ... new investors RusnanoMedInvest (RMI) and Arcus Ventures, existing ... Venture Investments, as well as undisclosed individual investors. ...
(Date:7/30/2014)... July 30, 2014 Company ... programming expertise to big data, aerospace and defense, ... eInfochips, a leading engineering R&D services company, today ... NVIDIA GPU-powered solutions for aerospace and defense ... (HPC), industrial , and visual ...
Breaking Medicine Technology:Medical Equipment Solutions Corp. Awarded $2 Million contract To Service DoD 2Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 2Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 3eInfochips to Develop NVIDIA GPU-powered Solutions for Aerospace and Defense, Medical Imaging, HPC and Visual Computing 2
... , , SOLON, Ohio, Dec. 16 ... of next generation technologies and a principal subcontractor for ... led development of new anthropromorphic arm technology that will ... and hand, including a sense of touch. , ...
... 16 A new application developed by American ... pharmaceuticals has increased health plan staff productivity and the number ... diagnostic imaging benefit management and technology company with health plan ... of WellPoint, Inc. (NYSE: WLP ), adapted the ...
Cached Medicine Technology:HDT Develops Robotic Arm Technology for DARPA's Revolutionizing Prosthetics 2009 Program 2American Imaging Management's New Specialty Drug Program Delivers Immediate Results 2American Imaging Management's New Specialty Drug Program Delivers Immediate Results 3American Imaging Management's New Specialty Drug Program Delivers Immediate Results 4
(Date:7/30/2014)... 30, 2014We have pills to ease pain, to cure infection, ... to enhance our sexual and athletic prowess. Why do pills ... we benefit from taking fewer pills? This provocative topic is ... and Fantasy of Pills in Modern Medicine ," published in ... peer-reviewed publication from Mary Ann Liebert, Inc., publishers. The article ...
(Date:7/30/2014)... Today, Gen. Arthur T. Dean, Chairman ... (CADCA) , the nation’s leading substance abuse prevention organization, ... New York Times Editorial Board’s call for marijuana ... , “CADCA is disappointed in the New York Times ... marijuana legalization. The move is shortsighted and completely disregards ...
(Date:7/30/2014)... 2014 (HealthDay News) -- Medical costs for chronic obstructive ... than $32 billion each year, according to new research ... The yearly financial toll of COPD (which includes ... estimated $49 billion by 2020. "For the first ... provide state public health practitioners with estimates of the ...
(Date:7/30/2014)... The Europe Phytochemicals & plant extracts market ... market in Europe with analysis and forecast of revenue. ... estimated to grow from around 710.18$ million in 2012 ... 8.4%, for the given period. , Browse through the ... report, to get an idea of the in-depth analysis ...
(Date:7/30/2014)... could help doctors decide which bladder cancer patients would ... according to a study* published in the British ... The University of Manchester, funded by the Medical Research ... levels of a protein, called ,HIF-1α, were more likely ... carbon dioxide gas and nicotinamide tablets at the ...
Breaking Medicine News(10 mins):Health News:CADCA Responds to New York Times Editorial Board's Call for Marijuana Legalization 2Health News:Annual COPD Costs To Hit $49 Billion by 2020: CDC 2Health News:Europe Phytochemicals & Plant Extracts (Nutraceuticals) Market is Expected to Reach $1,150.64 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Phytochemicals & Plant Extracts (Nutraceuticals) Market is Expected to Reach $1,150.64 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Phytochemicals & Plant Extracts (Nutraceuticals) Market is Expected to Reach $1,150.64 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Phytochemicals & Plant Extracts (Nutraceuticals) Market is Expected to Reach $1,150.64 Million in 2018 - New Report by MicroMarket Monitor 5Health News:Scientists pinpoint bladder cancer patients who could benefit from 'tumor-softening' treatment 2
... team of researchers at the John Hopkins Hospital in the US ... the PSA to detect prostate cancer.// ,The new test ... a simple blood test. ,Prostate cancer, the most ... of medicine. Physicians are unsure how to find it and when ...
... Thirteen year olds can perform cardiopulmonary resuscitation (CPR) as ... today. The authors suggest that children as young as ... chest compressions. ,Bystander CPR more than doubles ... arrest. Chest compressions are thought to be the most ...
... At least one-third of the time, the symptoms of ... in children, it can be difficult //to distinguish bipolar ... 2007 issue of the Harvard Mental Health Letter. ... the adult cycle of distinct mood episodes of mania ...
... are similar or better than those of whites when differences ... published in the American Heart Journal, Reuters reports. ... Rogers Memorial Veterans Hospital and colleagues studied the care and ... who were treated at five VA hospitals. ...
... Ahmed Obaid, Under-Secretary General and Executive Director of the ... Regional Director of UNFPA have// pressed the need for ... the highest maternal mortality rate in the world. More ... improve the health of the women and children. ...
... of the HIV eradication potential of a bone marrow transplant ... concluded that// eradication is unlikely utilising this method. ... reduce HIV to 'undetectable' levels in the blood, but they ... of our own cells. Although scientists have been working on ...
Cached Medicine News:Health News:New blood test to detect prostate cancer 2Health News:Priority Needs to Be Given to Maternal Health in Afghanistan 2Health News:HIV Eradication Unlikely Following Bone Marrow Transplantation 2Health News:HIV Eradication Unlikely Following Bone Marrow Transplantation 3
... Unparalleled Comfort Pick one of our pipettors ... the trigger and ejector positionsright where they should ... are ergonomically designed to help avoid repetitive stress ... Productivity In The Palm Of Your Hand ...
... multichannel has the same innovative ... model. The same universal handle ... five single channel tip cone ... recharge and storage stand with ...
... The Research pro Electronic Pipette is ideal ... laboratory. Its easy-to-follow display, ergonomically-placed operating buttons, ... dispensing, reverse pipetting and diluting make this ... simple functions of a manual pipette without ...
... Comfort Pick one of our pipettors up ... trigger and ejector positionsright where they should beeven ... ergonomically designed to help avoid repetitive stress injuries ... In The Palm Of Your Hand Start ...
Medicine Products: